BMS-790052: Phase IIa data

A double-blind Phase IIa trial in 48 patients showed that 3, 10 and 60 mg daily BMS-790052 plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) resulted in eRVR rates of ...